Credit Suisse AG Has $190,000 Stake in Geron Co. (GERN)

Credit Suisse AG lessened its position in Geron Co. (NASDAQ:GERN) by 23.5% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 107,630 shares of the biopharmaceutical company’s stock after selling 33,026 shares during the period. Credit Suisse AG owned about 0.06% of Geron worth $190,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Summit X LLC purchased a new position in shares of Geron during the second quarter valued at approximately $132,000. SG Americas Securities LLC increased its holdings in Geron by 352.2% during the second quarter. SG Americas Securities LLC now owns 57,936 shares of the biopharmaceutical company’s stock valued at $199,000 after buying an additional 45,124 shares during the last quarter. Seven Eight Capital LP purchased a new stake in Geron during the third quarter valued at approximately $123,000. MetLife Investment Advisors LLC increased its holdings in Geron by 72.3% during the second quarter. MetLife Investment Advisors LLC now owns 78,073 shares of the biopharmaceutical company’s stock valued at $268,000 after buying an additional 32,772 shares during the last quarter. Finally, Russell Investments Group Ltd. purchased a new stake in Geron during the third quarter valued at approximately $214,000. Hedge funds and other institutional investors own 30.67% of the company’s stock.

Shares of NASDAQ:GERN opened at $1.09 on Friday. Geron Co. has a fifty-two week low of $0.95 and a fifty-two week high of $6.99. The firm has a market cap of $203.12 million, a P/E ratio of -6.06 and a beta of 2.71.

Geron (NASDAQ:GERN) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.05) by $0.02. Geron had a negative net margin of 3,077.78% and a negative return on equity of 19.16%. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.22 million. On average, analysts expect that Geron Co. will post -0.2 EPS for the current year.

A number of analysts have commented on the stock. ValuEngine cut shares of Geron from a “hold” rating to a “sell” rating in a report on Monday, December 17th. S&P Equity Research reduced their price objective on shares of Geron from $2.32 to $1.80 in a research note on Thursday, September 27th. Zacks Investment Research cut shares of Geron from a “hold” rating to a “sell” rating in a research note on Thursday, October 4th. BidaskClub cut shares of Geron from a “sell” rating to a “strong sell” rating in a research note on Tuesday, November 13th. Finally, B. Riley cut shares of Geron from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $5.75 to $1.50 in a research note on Tuesday, October 2nd. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $3.76.

ILLEGAL ACTIVITY WARNING: This piece was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2019/01/20/credit-suisse-ag-has-190000-stake-in-geron-co-gern.html.

About Geron

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses.

See Also: Current Ratio

Want to see what other hedge funds are holding GERN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Geron Co. (NASDAQ:GERN).

Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Receive News & Ratings for Geron Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Geron and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply